Stanford Researchers Develop Potent New Drug Candidate Against SARS-CoV-2 Variants
Source-Getty-Images Stanford University researchers have unveiled a groundbreaking development in the fight against SARS-CoV-2, the virus responsible for the ongoing COVID-19 pandemic. Their discovery, detailed in a paper published in Science Translational Medicine on March 13, introduces a novel compound named ML2006a4 , designed at the atomic level to combat emerging coronavirus variants effectively. The research team, led by senior author Michael Lin, Associate Professor of Neurobiology and Bioengineering at Stanford, meticulously crafted ML2006a4 by customizing its atomic structure. This compound, akin to the current oral drug Paxlovid but with superior binding capabilities, demonstrates a remarkable ability to prevent the virus from replicating. Preclinical experiments on mice have shown that ML2006a4 outperforms Paxlovid in preventing deadly infections and exhibits potency against coronavirus variants resistant to existing treatments. The development of ML2006a4 stems ...